The relationship between otitis media with effusion (OME) and chronic rhinosinusitis with nasal polyposis (CRSwNP) 
Introduction
Otitis media with effusion (OME) can occur during the evolution of chronic rhinosinusitis with nasal polyps (CRSwNP). In our experience, the effusion is often highly viscous and difficult to treat. The pathophysiology of this OME remains unclear, which explains why a proper treatment is difficult to find.
In 2009, Parietti-Winkler et al reported an association between OME and nasal polyposis in a retrospective case-control study. 1 They found that OME appeared to occur in severe forms of nasal polyposis, especially in patients with asthma and aspirin hypersensitivity, and they presumed that OME might represent a sign of how serious the inflammatory process is in the upper airway.
We describe our study of the prevalence of OME in patients with CRSwNP. We also attempted to determine whether a relationship exists between the severity of CRSwNP and the presence of OME and whether risk factors for OME are detectable in a population of CRSwNP patients.
Patients and methods
For this cross-sectional study, we evaluated 80 consecutively presenting patients-42 males and 38 females, aged 15 to 76 years (median: 48)-who had been diagnosed with CRSwNP in the ENT department of a tertiary care center during a 2-year period from 2010 to 2012.
Our inclusion criteria included a minimum age of 15 years and the presence of CRSwNP previously diagnosed or diagnosed at study's onset by endoscopic nasal examination. Our exclusion criteria were the presence of a mucopurulent discharge or granuloma during endoscopic nasal examination, as defined in the European Position Paper on Rhinosinusitis and Nasal Polyps 2012.
In addition to demographic data, we compiled information on the family history of CRSwNP and asthma and the personal history of asthma, allergy, aspirin intolerance, intolerance of aspirin and/or nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin and/ or sulfite intolerance, aspirin-exacerbated respiratory disease, and tobacco addiction. In addition, we recorded data on the personal history of CRSwNP, the time of its onset, and previous surgical (e.g., polypectomy, ethmoidectomy) and medical treatments.
Sinonasal evaluation. At the onset of each patient's participation in this study, we evaluated several nasal signs and symptoms, including nasal congestion, hyposmia, sneezing, dull headache, and rhinorrhea; all were scored on a scale of 0 (absent) to 3 (very disturbing). On the same day, all patients underwent a bilateral endoscopic nasal examination to characterize the degree of nasal polyposis (NP grade) on each side. The NP grade was determined according to the Lildholdt classification:
• 0: no polyps; • 1: polyps in the middle meatus that do not reach the inferior rim of the middle turbinate;
• 2: polyps in the middle meatus that do reach the inferior rim of the middle turbinate; and
• 3: polyps in the nasal fossa that extend lower than the inferior rim of the middle turbinate. 3 An NP grade of 0 was assigned to patients who had been previously diagnosed with CRSwNP and successfully treated with intranasal steroids. The endoscopy was also performed to assess adenoid hypertrophy.
Computed tomography (CT) of the sinuses was performed when sinus surgery became necessary. The Lund-Mackay staging system was used to quantify the extent of the disease. 4 This classification is based on the analysis of CT opacity in the frontal sinus, anterior ethmoid cells, posterior ethmoid cells, maxillary sinus, sphenoid sinuses, and ostiomeatal complex on both sides. Each of these areas is given a score of either 0 (no opacity), 1 (partial opacity), or 2 (full opacity), and the global score thus ranges from 0 to 24.
Otologic evaluation. All patients underwent a complete evaluation of middle ear status. This included documentation of each patient's personal history of otologic disease, including acute otitis media and OME. We also collected information on the nature and duration of hearing loss, aural fullness, tinnitus, otalgia, otorrhea, and vertigo, as well as any previous myringotomy and ventilation tube (VT) insertion.
Each patient underwent an otoscopic examination and pure-tone audiometry with tympanometry on the same day. Air-and bone-conduction thresholds and pure-tone averages (PTAs) were calculated in the standard manner (average of 0.5, 1, 2, and 3 kHz, or 4 kHz if 3 kHz was not available) in accordance with the guidelines of the American Academy of Otolaryngology-Head and Neck Surgery. 5 The air-bone gap was reported as the four-tone PTA for air conduction minus the same average for bone conduction. Tympanograms were categorized according to the shape of the plot (A: normal; B: flat; C: shifted negatively on the graph). 6 OME was diagnosed on the basis of otoscopic findings associated with a B or C tympanogram.
Finally, we classified patients on the basis of the presence (OME+ group) or absence (OME-) of OME.
Statistical analysis. Data were analyzed with the use of the R statistical package. 7 Nominal variables were compared with the Fisher exact test, and quantitative variables with the Student t test or, if the normality assumption could not be sustained, with the Wilcoxon exact test.
Because this study is based on a retrospective review of medical charts, some minor data points are missing because not all information on every patient was contained in every chart. In such instances, percentages of patients were computed on the basis of the total number for whom data were available. A further explanation is provided in the tables as necessary.
Ethical considerations. All the procedures performed in this study were done in accordance with the ethical standards of the Institutional Research Committee of the Fondation Ophtalmologique Adolphe de Rothschild and the 1964 Declaration of Helsinki and its later amendments. Informed consent was obtained from all participants.
Results
Before our initial evaluation, 63 patients (78.8%) had already been treated for CRSwNP with an intranasal corticosteroid and 45 (56.3%) with a short course of an oral corticosteroid (some had received both). In addition, 30 patients (37.5%) had previously undergone surgery-endoscopic ethmoidectomy in 19 cases, polypectomy in 12, and turbinoplasty in 4 (some underwent more than one procedure). OME prevalence. At our first evaluation, OME was present in 20 patients (25.0%). In all, 38 ears were affected; OME was bilateral in 18 patients and unilateral in 2.
Of the 60 patients in the OME-group (75.0%), none developed OME during the entire follow-up period.
The two groups were comparable at baseline in terms of demographic variables (table 1). CRSwNP had been diagnosed at the median age of 41 years in the OME+ group and 35 years in the OME-group (p = 0.226). At our first evaluation, the respective median ages were 56 and 47 years (p = 0.136).
Previous treatment. We looked at the number of patients in each group who had previously undergone medical and surgical treatment for CRSwNP (table 1) . Only 8 patients (10.0%) had not been previously treated either surgically or medically for their CRSwNP.
Drug treatment. CRSwNP had already been medically treated with an intranasal steroid and/or a short course of an oral corticosteroid in 19 patients in the OME+ group (95.0%) and 50 patients in the OME-group (83.3%). In the OME+ group, 16 patients (80.0%) had taken an intranasal corticosteroid and 12 (60.0%) an oral corticosteroid (some had taken both). In the OMEgroup, 47 patients (78.3%) had taken an intranasal corticosteroid and 33 (55.0%) an oral corticosteroid (some had taken both).
Surgery. In OME+ group, 11 patients (55.0%) had previously undergone surgery-endoscopic ethmoidectomy in 6 cases, polypectomy in 4 cases, and turbinoplasty in 1. Only 19 patients (31.7%) in the OME-group had previously undergone surgery, but the difference was not statistically significant.
During the study, sinus surgery was performed on 4 patients in the OME+ group (2 polypectomies and 2 endoscopic ethmoidectomies) and on 8 patients in OME-group (7 endoscopic ethmoidectomies and 1 polypectomy).
Risk factors for OME. In comparing the OME+ and OME-groups, we found that the risk of OME was not significantly associated with a personal history of asthma, allergy, aspirin intolerance, aspirin and/or NSAIDs intolerance, aspirin and/or sulfite intolerance, or aspirin-exacerbated respiratory disease (AERD) (i.e., the Samter triad-a combination of nasal polyposis, asthma, and aspirin intolerance) (table 2) . Nasal symptoms. No significant differences between the OME+ and OMEgroups were observed in symptom scores for nasal congestion, hyposmia, sneezing, and dull headache. There was a trend toward higher rhinorrhea scores in the OME+ group, but the difference did not reach statistical significance (p = 0.054) (table 3) .
In most OME+ patients (13 of 17 for whom data were available), nasal symptoms appeared before otologic symptoms; in the other 4, the otologic symptoms appeared first. The average delay between the onset of nasal and otologic symptoms was 10 years (±7.8).
NP grades. Among the 79 cases for which data were available, the NP grade was 0 in 8 patients ( Among the 59 cases for which data were available in the OME-group, the NP grade was 0 in 7 patients (11.9%), 1 in 15 patients (25.4%), 2 in 13 patients (22.0%), 3 in 13 patients, and 4 in 11 patients (18.6%).
The distribution of NP grades was not significantly different between the OME+ and OME-groups (p = 0.82).
We also studied the distribution of NP grades between the 38 OME+ ears and 122 of the OME-ears and found no significant difference (p = 0.23).
Additionally, we compared NP grades between patients who had previously undergone surgery for CRSwNP and those who had not. Again, we found no significant difference (p = 0.48).
Finally, no adenoid hypertrophy was observed in any patient.
CT results. A total of 58 patients underwent CT-16 in the OME+ group and 42 in the OME-group. The mean Lund-Mackay score was 12.5 ± 5.5 in the OME+ group and 12.8 ± 4.6 in the OME-group, which is not significantly different (p = 0.95).
Otologic symptoms. In the OME+ group, 9 patients (45.0%) had a personal history of acute otitis media, 14 (70.0%) had a previous history of OME, 7 (35.0%) had previously undergone myringotomy, and 4 (20.0%) had received a VT to treat OME.
In the OME+ group, hearing loss was reported by 17 patients (85.0%), otalgia by 7 (35.0%), and aural fullness VT insertion. Four of the patients with hearing loss had previously undergone myringotomy with VT insertion; 1 of these 4 had undergone two VT insertions, which had been performed 2 and 4 years earlier.
Five patients underwent VT insertion during the study because of persistent OME that had resulted in disabling hearing loss despite oral corticosteroid treatment. For these 5 patients, the mean air-conduction PTA was 54.0 dB (range: 33.5 to 88.8), and the mean bone-conduction PTA was 32.9 dB (range: 15.0 to 67.5). The mean air-bone gap was 21.1 dB (range: 6.3 to 45.0). Myringotomy resulted in the drainage of highly viscous middle ear fluid in each patient.
Two patients presented with a post-VT residual tympanic membrane perforation associated with highly viscous effusion in the middle ear. A fluid sample was harvested for cytologic analysis from patients with a VT or a perforation, as well as during myringotomy. Only 3 samples were available for cytologic analysis; mucus contained many eosinophils in 2 of them.
Discussion
In our study, OME was present in 20 of the 80 patients (25.0%) with CRSwNP. This relatively high percentage can probably be explained by selection bias, as the patients we recruited were seen at a tertiary care medical center, where difficult cases are referred for expert opinion. Based on our experience, OME in patients with CRSwNP appears to be rather severe and poorly responsive to standard treatments. The effusion is often highly viscous and can obstruct a VT. The relationship between OME and CRSwNP is poorly described in the literature. 8 In 2009, Parietti-Winkler et al were the first to highlight the association between OME and nasal polyposis in their retrospective study. 1 The mechanism is not well understood. Two possible causes are (1) obstruction of the eustachian tube by polyps or by congestion of the nasopharyngeal mucosa and (2) the presence of a common inflammatory disease that affects both the nasal and middle ear mucosae.
Based on our findings, the first hypothesis appears to be less likely than the second because we found no relationship among endoscopic NP grades, nasopharyngeal endoscopy findings, and the onset of OME. Moreover, nasal congestion and Lund-MacKay scores were not significantly different between our OME+ and OME-groups. Therefore, OME could not be explained by an obstruction of the eustachian tube by polyps or by hyperplasia of the nasopharyngeal mucosa. We can also rule out congestion of the respiratory mucosa. The more likely explanation is the presence of a common disease that involves the entire mucosa of the upper airways, including the middle ear mucosa.
Allergic disease may affect the entire respiratory tract mucosa. Indeed, the relationships between OME and allergic rhinitis [9] [10] [11] and between allergic rhinitis and asthma 12 have been previously reported. However, in our population, we found no link between OME and a history of asthma, allergy, or aspirin intolerance. Like us, Parietti-Winkler et al found no difference in the proportion of patients with asthma or atopy between cases and controls. 1 They also reported that the risk of OME in patients with nasal polyposis was five times higher when patients presented with AERD. On the other hand, we found no link between OME and AERD. Therefore, solitary asthma and solitary allergy are probably not risk factors for OME in nasal polyposis patients. We believe that the reason our results differ from those of Parietti-Winkler et al with respect to AERD might be that the number of OME+ patients in our study was small.
We found that a higher proportion of OME+ patients had already undergone a nasal surgical procedure compared with the OME-patients, but the difference was not statistically significant, probably due to the small number of patients. A significant difference was reported by Parietti-Winkler et al, who estimated that previous surgery for CRSwNP was associated with a threefold higher risk of OME development. 1 We believe that previous surgery is a marker of severity in CRSwNP, and therefore patients with more severe CRSwNP are at greater risk of developing OME. Indeed, severe cases of CRSwNP that cause disturbing symptoms despite medical treatment usually respond to surgical treatment. Nevertheless, we found that NP grade was not correlated with previous nasal surgery. However, this is easily explained because NP grades are generally low after surgery and local treatment.
In our study, the onset of OME was not significantly correlated with polyp size. Our data showed that OME can develop or persist even when obstructive nasal symptoms are well controlled. On the other hand, rhinorrhea is the expression of nasal mucosa hypersecretion in inflammatory conditions. Thus, the problem is probably located in the mucus and even more so in the mucosa that produces it. The whole mucosa of the upper respiratory tract, including the middle ear, is probably affected by an inflammatory condition, explaining the rhinorrhea and the highly viscous middle ear effusion.
We were able to analyze middle ear effusion in only 3 patients, and we found local hypereosinophilia in 2 of them. In 2002, Nagamine et al in Japan described a different kind of OME that features highly viscous effusion that contains many eosinophils, a condition they called eosinophilic otitis media (EOM). 13 This and subsequent Japanese studies found that this condition was often related to asthma and nasal polyposis. [13] [14] [15] [16] EOM is also known to be difficult to treat. 16 Moreover, it can lead to a deterioration of bone-conduction hearing levels. 17, 18 A long duration of EOM could increase this risk. 17 Otoscopic evaluation of each patient with CRSwNP should be performed because OME occurs frequently during the evolution of the disease, even when the nasal symptoms are well controlled. When OME is present, a systematic analysis of the effusion should be performed. If many eosinophils are present, systemic or topical steroid administration might be effective. 16 Other treatments such as anti-IgE are being tested. 19 Patients must be warned of the risk of sensorineural hearing loss.
In conclusion, OME is a common condition in patients with CRSwNP. ENT specialists should pay special attention to the middle ear examination in patients with CRSwNP. Conversely, a rhinologic evaluation is required in cases of OME, especially when a highly viscous effusion is present.
Even though many questions remain concerning the pathophysiology of OME in CRSwNP, OME seems more likely to be an expression of an inflammatory disease that extends to the middle ear rather than a consequence of the nasal disease itself. 
